Clinical Trials · NCT01179048
Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 9,341
- Start date
- Aug 2010
- Locations
- 428 sites, 33 countries
- Primary endpoint
- Time From Randomisation to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome)